Anti-CD7 CAR-T Cells for T-Cell Leukemia/Lymphoma
This study is testing an investigational treatment called BEAM-201 for people aged 0 to 29 with T-Cell Acute Lymphoblastic Leukemia or Lymphoma (T-ALL/T-LLy) that has come back or not responded to previous treatments. BEAM-201 is a type of CAR-T cell therapy, which uses specially modified immune cells to fight cancer. Researchers want to find the safest dose of BEAM-201 and understand any side effects over five years. This is an early-stage study, and it aims to enroll 33 participants. The study is currently open, but its exact status is unclear.
- Study design
- This is a Phase 1, open-label study designed to evaluate the safety and effectiveness of BEAM-201 in approximately 33 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for five years to measure the maximum tolerated dose and frequency of adverse events.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
At a glance
Conditions
NCT06934382
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Children's Hospital of Philadelphia
Philadelphia, Pennsylvaniastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Caroline Diorio, MD · PRINCIPAL_INVESTIGATOR · Children's Hospital of Philadelphia
- Stephan Grupp, MD, PhD · STUDY_DIRECTOR · Children's Hospital of Philadelphia
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Determine the Maximum Tolerate Dose of Beam 201 Cells5 years
The Maximum Tolerated Dose will be determined by measuring the incidence of dose limiting toxicities following administration of the product.
- Frequency of Adverse Events Following Beam-201 administration5 years
Frequency of Adverse events will be measured by evaluating the frequency and severity of treatment related adverse events following administration of Beam-201 Cells